PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsglioblastoma
MeSH D005909 - glioblastoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001254:Astrocytoma
$
Success rate
D005909: 
Glioblastoma
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaTemozolomide Temozolomide Teva  2010-01-28   
IngenusCarmustine Carmustine  2022-06-21   
MylanBevacizumab Abevmy  2021-04-21   
Bevacizumab Lextemy     
Carmustine Carmustine  2023-03-03   
Rising PharmaceuticalsTemozolomide Temozolomide  2016-06-29   
RocheBevacizumab Avastin  2005-01-12 $1,987.484 M Q4/22-Q3/23 
SandozTemozolomide Temozolomide Sandoz  2010-03-15   
Merck & CoTemozolomide Temodal  1999-01-26   
Temozolomide Temodar  1999-08-11 $215 M Y2018 
PfizerBevacizumab Zirabev  2019-06-27 $424 M Y2023 
Dr Reddys LaboratoriesCarmustine Carmustine  2020-10-22   
Zydus TherapeuticsTemozolomide Temozolomide  2017-07-31   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
76%
158/209
Phase 2
15%
35/232
Phase 3
10%
4/40
Approved: 2Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Mylan
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use